These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 4698011)
1. [New methods for measurement of the tremor and rigidity in patients with Parkinson's disease treated with L-Dopa]. Paci A; Freddi A; Barba C Riv Neurol; 1973; 43(1):15-39. PubMed ID: 4698011 [No Abstract] [Full Text] [Related]
2. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report. Wycis HT Confin Neurol; 1972; 34(2):130-5. PubMed ID: 4666056 [No Abstract] [Full Text] [Related]
3. [Monosynaptic reflex in patients with Parkinson's disease treated with L-dopa]. Palao Sánchez A Arch Neurobiol (Madr); 1974; 37(1):1-10. PubMed ID: 4838663 [No Abstract] [Full Text] [Related]
5. Influence of L-dopa on the EEG and EMG in Parkinson patients. Visser SL; Postma JU Psychiatr Neurol Neurochir; 1971; 74(4):315-21. PubMed ID: 5146237 [No Abstract] [Full Text] [Related]
6. [Efficacy and side effects of L-dopa in patients with Parkinson's syndrome]. Lombardo L Arch Invest Med (Mex); 1973; 4(3):215-24. PubMed ID: 4784173 [No Abstract] [Full Text] [Related]
8. The effect of L-dopa treatment on the speech of patients with Parkinson's disease. Audelman JU; Hoel RL; Lassman FM Neurology; 1970 Apr; 20(4):410-1. PubMed ID: 5535064 [No Abstract] [Full Text] [Related]
9. [Experiences with L-DOPA (Eldopal) treatment of 40 patients with Parkinson's disease]. Postma JU; Stam FC; Meerlo HJ Ned Tijdschr Geneeskd; 1971 Apr; 115(16):701-7. PubMed ID: 5551426 [No Abstract] [Full Text] [Related]
10. [Disulfiram and L-dopa in patients with Parkinson's syndrome and in torsion dystonia]. Serrano PA; Irigoyen M Prensa Med Mex; 1972; 37(7):246-50. PubMed ID: 4646433 [No Abstract] [Full Text] [Related]
11. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report. Wycis HT Confin Neurol; 1972; 34(1):130-5. PubMed ID: 5084387 [No Abstract] [Full Text] [Related]
12. [Silent period in patients with Parkinson's disease treated with L-Dopa]. Palao Sánchez A Arch Neurobiol (Madr); 1973; 36(1):47-56. PubMed ID: 4706780 [No Abstract] [Full Text] [Related]
13. L-dopa therapy in Parkinson's disease. Lipman IJ Va Med Mon (1918); 1971 May; 98(5):242-8. PubMed ID: 4931138 [No Abstract] [Full Text] [Related]
14. Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa. Parkes JD; Marsden CD; Rees JE; Curzon G; Kantamaneni BD; Knill-Jones R; Akbar A; Das S; Kataria M Q J Med; 1974 Jan; 43(169):49-61. PubMed ID: 4822972 [No Abstract] [Full Text] [Related]
15. [L-Dopa in the treatment of Parkinson's disease. (Considerations on 51 cases)]. Mazza C; Buffatti PF; Bazzan A; Lion P Fracastoro; 1970; 63(5):768-73. PubMed ID: 5519378 [No Abstract] [Full Text] [Related]
16. Quantitative measurements of L-dopa therapy in Parkinson's disease. Webster DD Trans Am Neurol Assoc; 1969; 94():348-50. PubMed ID: 5374483 [No Abstract] [Full Text] [Related]
17. [Current treatment of Parkinson syndrome with L-dopa]. Gerstendbrand F; Gründig E; Musiol A Pol Tyg Lek; 1972 May; 27(21):798-800. PubMed ID: 4555002 [No Abstract] [Full Text] [Related]